Clinical trials using CXCR1 and CXCR2 inhibitors revealed that they are successful in treating patients with chronic diseases (e.g., COPD), whereas their use can be detrimental in patients with viral infection. This evidence concerns the gene CXCR2 and viral infectious disease.